Abstracts tagged "SLE"

Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting
A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine I. Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Kelly Rouster-Stevens⁸, Laura E. Schanberg⁹, Marisa Klein-Gitelman¹⁰, Emily von Scheven¹¹ and CARRA Registry Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁹Pediatrics, Duke Medical Center, Durham, NC, ¹⁰Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
Abstract Number: 1836 • 2016 ACR/ARHP Annual Meeting
SLE Bone Marrow Contains Factors That Promote Type I Interferon Activation
Nida Meednu¹, Anna Bird², Jennifer Barnard², Mariana Kaplan³ and Jennifer H. Anolik², ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: SLE is characterized by the inappropriate activation of type I Interferon (IFN) and increases in apoptosis and NETosis by neutrophils, which in combination with…
Abstract Number: 2832 • 2016 ACR/ARHP Annual Meeting
Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus
Dag Leonard¹, Andrei Alexsson¹, Johanna Dahlqvist², Kimberly Taylor³, Johanna K Sandling⁴, Christine Bengtsson⁵, Elisabet Svenungsson⁶, Christopher Sjöwall⁷, Andreas Jönsen⁸, Iva Gunnarsson⁶, Anders A. Bengtsson⁸, Solbritt Rantapaa-Dahlqvist⁵, Maija-Leena Eloranta¹, Ann-Christine Syvänen⁴, Lindsey A. Criswell⁹ and Lars Rönnblom¹, ¹Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ²Uppsala University, Department of Medical Biochemistry and Microbiology Science for Life Laboratory, Uppsala, Sweden, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Uppsala University, Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala, Sweden, ⁵Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden, ⁶Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ⁷Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ⁸Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Methods: An association between a locus located on chromosome 14 and stroke/TIA was shown in both the Swedish (OR 1.8, p=0.0002) and the US…
Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting
Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Yenealem Temesgen-Oyelakin², Maureen Sampson³, Aditya Joshi⁴, Alice Fike⁵, Michael Davis⁶, Taufiq Salahuddin⁷, Balaji Natarajan⁷, Joseph Lerman⁷, Zerai G. Manna⁸, Amit Dey⁹, Marcus Chen⁷, Sarfaraz Hasni⁸, Nehal N. Mehta⁷, Alan Remaley⁷ and Mariana Kaplan¹⁰, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹National Institutes of Health, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD
Background/Purpose: The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…
Abstract Number: 753 • 2016 ACR/ARHP Annual Meeting
Vitamin D Improves Systolic Blood Pressure in SLE
Michelle Petri¹, Erik Barr² and Laurence S Magder³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Both a cohort study and a randomized clinical trial have proven that Vitamin D supplementation improves SLE…
Abstract Number: 999 • 2016 ACR/ARHP Annual Meeting
Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Sajal Ajmani, Harshit Singh, Saurabh Chaturvedi, Mohit kumar Rai and Vikas Agrawal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Fever is a common presenting manifestation of systemic lupus erythematosus (SLE) and ANCA associated vasculitis (AAV). Treating physician is challenged to differentiate between disease…
Abstract Number: 1749 • 2016 ACR/ARHP Annual Meeting
The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis
Goh Murayama¹, Asako Chiba², Hirofumi Amano³, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake⁴, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan, ⁴Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by MHC-related molecule-1 (MR1) and express a semi-invariant TCRa chain: Va7.2-Ja33 in…
Abstract Number: 1843 • 2016 ACR/ARHP Annual Meeting
Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established SLE-Risk Loci in Lupus Patient Monocytes
Yogita Ghodke-Puranik¹, Zhongbo Jin¹, Wei Fan², Mark A. Jensen³, Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin⁴, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁴, Kevin Moder⁴, Vaidehi Chowdhary⁴ and Timothy B. Niewold⁶, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China, ³Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: While most of the confirmed SLE-risk loci are in or near genes with immune system function, a major unanswered question is how these loci…
Abstract Number: 2840 • 2016 ACR/ARHP Annual Meeting
Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
Sasha Bernatsky¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Patrick Gaffney⁴, John Spinelli⁵, Sophia Wang⁶ and Timothy J. Vyse⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁶Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
Are there genetic predispositions to diffuse large B-cell lymphoma (DLBCL) in systemic lupus (SLE)? Sasha Bernatsky1, Ann E. Clarke2, Rosalind Ramsey-Goldman3, Patrick M. Gaffney4,…
Abstract Number: 3105 • 2016 ACR/ARHP Annual Meeting
Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Ricardo Marques¹, Laura Heretiu², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Serviço de Medicina Interna B, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Medicine, Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rituximab (RTX) has been used off-label in refractory SLE with variable clinical outcomes in different cohorts, with no predictive response markers available. However, the…
Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Sharzad Emamikia¹, Cidem Gentline², Magnus Backheden³, Katerina Chatzidionysiou², Laurent Arnaud⁴ and Ronald F. van Vollenhoven^2,5, ¹Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, ⁴Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…
Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
John McKinnon¹, Junying Zhou², Jenna Hudy¹, Sara Hegab¹ and Kathleen Maksimowicz-McKinnon³, ¹Henry Ford Hospital, Detroit, MI, ²Infectious Diseases, Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
Abstract Number: 1754 • 2016 ACR/ARHP Annual Meeting
Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice
Ken Tsumiyama¹, Chieri Akiyama², Yumi Miyazaki¹, Yasushi Miura², Akira Hashiramoto² and Shunichi Shiozawa¹, ¹Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ²Department of Biophysics, Kobe University Graduate School of Health Science, Kobe, Japan
Background/Purpose: Previous studies strongly suggest that interferon α (IFNα) may be the principal driver of SLE, where increased IFNα and IFNα-regulated gene transcripts explain many of the immune…
Abstract Number: 1910 • 2016 ACR/ARHP Annual Meeting
IL-21 Inhibits Treg Differentiation and Function in SLE By Modulating GATA-3 and CTLA-4
Hiroshi Kato¹ and Andras Perl², ¹Division of Rheumatology/Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Department of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Studies indicate quantitative and qualitative Treg insufficiencies underlying the dysregulated immune response in SLE. However, it is unknown what mechanisms drive the Treg dysfunction…
Abstract Number: 2850 • 2016 ACR/ARHP Annual Meeting
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Joan Wither¹, Stephenie Prokopec², Babak Noamani¹, Dennisse Bonilla¹, Zahi Touma³, Carmen Avila-Casado⁴, Heather Reich⁵, James Scholey⁵, Paul R. Fortin⁶, Paul Boutros² and Carolina Landolt-Marticorena¹, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Pathology, University Health Network, Toronto, ON, Canada, ⁵Nephrology, University Health Network, Toronto, ON, Canada, ⁶Université Laval, CHU de Québec, Québec, QC, Canada
Background/Purpose: The relapsing and remitting nature of lupus nephritis (LN) poses a challenge to clinicians who must balance the risk of long term kidney damage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].